Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Conditions
Hepatitis B Virus
What is the purpose of this trial?
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB)
Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda (Lambda) when administered in combination with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic hepatitis B(CHB) infection employing a sequential therapy approach
Participation Guidelines
- Age:
- 18 Years - 70 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Bristol-Myers Squibb
- Dates:
- November 2010
- Last Updated:
- March 28, 2013
- Study HIC#:
- 1009007449
Clinicaltrials.gov ID: NCT01204762
